Health
Red flags for colorectal cancer that warrant screenings before 45 years of age
NEWYou can now listen to Fox News articles!
Colorectal cancer (CRC) is now the leading cause of cancer death in adults under 50 and the second leading cause of cancer death in the U.S., highlighting the importance of routine screenings.
Adults 65 and younger comprise nearly half (45%) of all new cases — a significant increase from 27% in 1995, according to a report from the American Cancer Society.
“Once considered a disease that primarily affected people over 50, we are now seeing increasing diagnoses in patients in their 20s, 30s and 40s — making it even more important not to dismiss symptoms based on age alone,” Dr. Timothy Cannon, director of the Molecular Tumor Board and co-director of the Gastrointestinal Cancer Program at Inova in Virginia, told Fox News Digital.
SPIKE IN DEADLY CANCER BEFORE 50 LINKED TO COMMON CONVENIENCE FOODS
Official health agencies recommend that CRC screenings start at age 45 and continue through age 75 for adults at “average risk.”
Stool-based tests can be used to detect blood or DNA changes, potential indicators of cancer. Depending on the type of stool test, it can be performed every one to three years.
Colorectal cancer is now the leading cause of cancer death in adults under 50 and the second leading cause of cancer death in the U.S. (iStock)
A colonoscopy is a medical procedure that allows a doctor to examine the inside of the patient’s colon and rectum using a thin, flexible tube with a camera on the end. For average-risk adults, a colonoscopy is typically done every 10 years.
“Colonoscopy remains the gold standard because it not only detects cancer early, but can also prevent it by identifying and removing precancerous polyps,” Cannon said.
JAMES VAN DER BEEK’S DEATH HIGHLIGHTS ALARMING COLON CANCER RISE IN YOUNGER ADULTS
Dr. Michael Martin, a California physician, emphasized that colonoscopy is generally preferred for younger patients who are clearly at higher risk.
“Stool-based tests are appropriate screening options for average-risk adults, but they are not the best choice for people with significant family history, inflammatory bowel disease, hereditary syndromes or alarm symptoms,” he told Fox News Digital. “If symptoms are present, the goal is not screening but diagnosis, and colonoscopy is usually the more appropriate test.”
3 reasons to get screened before 45
Doctors may suggest earlier screenings for people who fall into the following higher-risk groups.
Strong family history
“A family history can make screening earlier and more frequent,” Martin told Fox News Digital.
The American College of Gastroenterology recommends early screening if one first-degree relative is diagnosed with colorectal cancer or an advanced polyp before age 60, or if two first-degree relatives are diagnosed at any age.
A colonoscopy is a medical procedure that allows a doctor to examine the inside of the patient’s colon and rectum using a thin, flexible tube with a camera on the end. (iStock)
“They should generally start colonoscopy at age 40 or 10 years before the youngest affected relative’s diagnosis, whichever comes first,” Martin said. “In that setting, repeat the colonoscopy every five years is then generally recommended.”
Critical symptoms
Cannon listed the following red flags that warrant earlier screenings.
NEARLY 40% OF CANCERS CAN BE PREVENTED WITH 3 LIFESTYLE CHANGES, STUDY FINDS
- Rectal bleeding with bright-red blood
- Dark or black stools
- Blood in the stool
- Persistent changes in bowel habits, such as new constipation or diarrhea
- Unexplained iron-deficiency anemia
- Ongoing abdominal pain or cramping
- Unexplained weight loss
- Persistent sensation that the bowel is not emptying fully
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“While many of these symptoms can be caused by less serious conditions, they should never be ignored,” he said.
Ongoing abdominal pain or cramping is one warning sign that could warrant earlier screenings. (iStock)
Rectal bleeding in particular should always be taken seriously, even in younger patients, Cannon said.
“Too often, symptoms are attributed to hemorrhoids, diet, stress or athletic activity without further evaluation,” he noted. “Any persistent or unexplained bleeding warrants a conversation with a physician, and in some cases, a colonoscopy.”
“If something feels new, persistent, or concerning, don’t wait. Early evaluation can save your life.”
Certain genetic conditions
Some common hereditary syndromes increase the risk of colorectal cancer and may warrant earlier screenings.
For example, people with Lynch syndrome — an inherited DNA mutation that greatly increases lifetime risk — should get a colonoscopy every one to two years starting at about 20–25 years old or two to five years before the youngest diagnosed family case, according to the National Cancer Institute.
Familial Adenomatous Polyposis (FAP), another genetic variant, carries the risk of thousands of polyps and a nearly 100% lifetime risk of CRC, noted the American Cancer Society. Those with FAP are advised to start annual screenings at as early as 10 to 12 years old.
Several other syndromes and genetic variations — including Peutz–Jeghers Syndrome, Juvenile Polyposis Syndrome and MUTYH-Associated Polyposis (MAP) — can also warrant earlier screenings.
Inflammatory bowel disease
Those with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, face a higher lifetime risk of developing colorectal cancer, according to the Centers for Disease Control and Prevention.
CLICK HERE FOR MORE HEALTH STORIES
This is largely due to chronic inflammation that causes cellular changes. In this case, the patient may be advised to start colonoscopy screenings before age 45.
If someone falls into a category that warrants an early screening before 45, and then the screening is normal, the length of time until the next one will depend on the specific risk factors, according to Martin.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“If it was performed because of a strong family history, repeating it every five years is common,” he advised. “If the person turns out not to have colon cancer (or an advanced polyp) and is closer to average risk than to high risk, the interval may be longer.”
In many cases, early screenings will be covered by insurance, Martin said, but coverage rules can differ depending on whether the exam is classified as screening or diagnostic.
Those with inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, face a higher lifetime risk of developing colorectal cancer. (iStock)
“Under federal law, recommended screening tests for average-risk patients are generally covered without cost-sharing, but a colonoscopy done because of symptoms is often considered diagnostic, as mentioned above,” he noted. “This can have an impact on deductibles or co-pays. The exact out-of-pocket cost varies by insurer and plan.”
The encouraging news is that colorectal cancer is often preventable, Cannon emphasized.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“Most cancers develop slowly from precancerous polyps over many years,” he said. “Screening allows physicians to detect and remove these polyps before they turn into cancer.”
“The key message: If something feels new, persistent, or concerning, don’t wait. Early evaluation can save your life.”
Health
A Healthy ‘Hyperfixation Meal’ Helps You Lose Weight Faster—Without Dieting
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Health
Pancreatic cancer patient Ben Sasse sees ‘massive’ tumor reduction with experimental new drug
NEWYou can now listen to Fox News articles!
Months after revealing his stage 4 cancer diagnosis, former U.S. Sen. Ben Sasse is speaking out about an experimental therapy that could extend his life.
Sasse, a Republican who represented Nebraska between 2015 and 2023, shared in December 2025 that he has metastatic pancreatic cancer, which has spread to multiple organs — including his liver and lungs.
After initially being given three to four months to live, Sasse, 54, entered a clinical trial for a drug called daraxonrasib, an oral therapy (pill) that is designed to block the defective gene that triggers uncontrolled cellular growth.
CANCER SURVIVAL APPEARS TO DOUBLE WITH COMMON VACCINE, RESEARCHERS SAY
The California-based drugmaker, Revolution Medicines, recently shared data from a phase 3 clinical trial of people with metastatic pancreatic cancer who did not respond to standard chemotherapy.
Patients on the treatment lived a median of 13 months, compared to around six months for those who continued with chemo.
Former Sen. Ben Sasse of Nebraska entered a clinical trial for a drug called daraxonrasib, an oral therapy (pill) that is designed to block the defective gene that triggers uncontrolled cellular growth. (Anna Moneymaker/Getty Images)
“I have much, much less pain than I had four months ago when I was diagnosed, and I have a massive 76% reduction in tumor volume over the last four months,” Sasse told “60 Minutes” in a recent interview.
Daraxonrasib works by going after a key growth “switch” in many cancers called RAS, according to Sarbajit Mukherjee, M.D., chief of gastrointestinal medical oncology at Miami Cancer Institute, part of Baptist Health South Florida.
MAN WITH STAGE 4 CANCER RAISES $150K FOR EXPERIMENTAL TREATMENT
“In pancreatic cancer, that switch is stuck in the ‘on’ position in the vast majority of tumors, constantly telling the cancer cells to grow and spread,” the doctor, who was not involved in the trial and did not treat Sasse, told Fox News Digital.
“Daraxonrasib is designed to bind to RAS in its active state and turn down that signal, which can slow or shrink the cancer.”
“The drug is in the final stages of clinical trials, where it has been shown to double the survival of those previously treated for metastatic pancreatic cancer.”
Pancreatic cancer is difficult to diagnose early because there are generally no symptoms — or only subtle gastrointestinal symptoms — until it is already widespread, according to Dr. Marc Siegel, Fox News senior medical analyst.
“This is the first-of-its-kind targeted therapy for pancreatic cancer,” Siegel, who also was not involved in the research or the senator’s treatment, told Fox News Digital. “The drug is in the final stages of clinical trials, where it has been shown to double the survival of those previously treated for metastatic pancreatic cancer.”
Sasse, shown above, announced his diagnosis late last year. An expert noted that the survival boost seen from the clinical trial is a “big difference” for a disease that typically has much shorter survival times. (Win McNamee/Getty Images)
Mukherjee noted that the survival boost seen in the trial is a “big difference” for a disease that typically has much shorter survival times.
“From my perspective, as someone who treats pancreatic cancer every day, daraxonrasib is the first targeted pill in this disease that truly feels like a step change rather than a small incremental improvement,” he said.
“It opens the door to much more personalized strategies going forward. For a cancer where progress has been painfully slow, it could reshape how we care for patients with advanced disease.”
RECTAL CANCER DEATHS RISING UP TO THREE TIMES FASTER IN SPECIFIC AGE GROUP, STUDY FINDS
While current chemotherapy options can shrink pancreatic tumors and help people live longer, they are “tough,” Mukherjee noted — “and once they stop working, our options are limited and survival is usually measured in just a few more months.”
Early data also suggest that when daraxonrasib is combined with standard chemotherapy as the first treatment, there is more shrinkage of tumors and more patients doing well at six months than they typically would only with chemotherapy.
Sasse shared in December 2025 that he has metastatic pancreatic cancer, which has spread to multiple organs, including his liver and lungs. (Meghan McCarthy/Palm Beach Daily News/USA TODAY NETWORK via Imagn Images)
If the drug is approved, it will likely become an important option for patients when standard chemotherapy stops working, Mukherjee suggested.
“Ongoing trials are now asking whether it should also be used as part of the very first treatment plan,” he added.
NEW CANCER VACCINE SHOWS PROMISING RESULTS FOR CERTAIN PATIENTS
Although the drug is described as “well-tolerated” compared to chemotherapy, the doctor noted that, like any strong cancer drug, daraxonrasib has side effects.
“The ones we see most often include rash, diarrhea, mouth sores and fatigue, with patients needing regular blood tests and close follow‑up while on treatment,” Mukherjee said.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
In the clinical trials, most of these problems have been managed by adjusting the dose or adding supportive medications.
“The limitations are important to be transparent about — it is still not yet FDA‑approved, and it is not a cure,” Mukherjee noted.
In addition to the daraxonrasi, Sasse credits his faith for helping him beat his original prognosis. (Drew Angerer/Getty Images)
“Over time, most cancers will eventually find ways to grow around the drug.”
CLICK HERE FOR MORE HEALTH STORIES
In addition to daraxonrasib, which he calls a “miracle” drug, Sasse credits his faith for helping him beat his original prognosis.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“It’s weird to be in your early 50s and get a terminal diagnosis, and people all of a sudden act like you’re 93 or 94, and you have a lot of wisdom,” he said.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“I don’t know that I have a lot of wisdom, but I have a lot of things that I think we should be reflecting on together.”
Fox News Digital reached out to Sasse for further comment, and to the head of the clinical trial as well.
Health
Supreme Court Appears Divided Over Roundup Weedkiller Case
The Supreme Court appeared divided on Monday during arguments in a dispute that could determine the fate of thousands of lawsuits that claim a widely used weedkiller causes cancer.
The case is the latest turn in a yearslong legal battle over safety concerns with the weedkiller Roundup. Developed by Monsanto in the 1970s, the herbicide is the focus of the lawsuits, which allege that it causes non-Hodgkin lymphoma.
The dispute before the justices stems from a 2019 lawsuit brought by a Missouri gardener, John Durnell, who used Roundup for years. Mr. Durnell claimed in his suit, filed in state court, that glyphosate, a chemical in the weedkiller, caused him to develop cancer.
During Monday’s oral argument, several of the justices expressed skepticism of arguments by Bayer, the German conglomerate that acquired Monsanto in 2018, and the Trump administration, which joined the case in support of the company, that federal rules requiring herbicide safety labeling should bar people from filing state-level claims that accuse companies of failing to warn consumers of dangers.
Chief Justice John G. Roberts Jr. asked a lawyer for the Trump administration whether states would be blocked from taking action if new scientific information raised alarms about a product.
“The states cannot do anything?” the chief justice asked.
Sarah M. Harris, a principal deputy solicitor general, responded that it would be problematic to have each state “jumping the gun” to come to its own conclusion about whether a product caused cancer.
Mr. Durnell’s lawyer argued that the federal Environmental Protection Agency had overreached its regulatory power, a problem that could be rectified by giving a role to the courts, including at the state level. Several of the justices appeared skeptical about that argument too, questioning whether such a ruling would lead to a patchwork of safety regulations throughout the country.
In 2023, a Missouri jury awarded Mr. Durnell $1.25 million in damages. If the court finds for the company, that verdict would be erased and other claims against the company also endangered. If the court finds for Mr. Durnell, not only would his verdict be upheld but it would also clear the way for a flood of other lawsuits to proceed in courts throughout the country.
A ruling is expected by the end of June or early July.
The central issue in the case involves a collision between state and federal power. Bayer has argued that Mr. Durnell’s victory in Missouri is barred by a federal law, the Federal Insecticide, Fungicide and Rodenticide Act. That statute requires herbicides to be registered with the E.P.A. before they can be sold. Companies must submit scientific and safety data to the agency, along with proposed label information, including safety warnings.
The E.P.A. has previously determined that Roundup is safe to use. Bayer argued that the Missouri court ruling conflicted with that federal determination. Paul D. Clement, who represented Bayer, asserted that the federal agency’s decision invalidates the state court decision.
Got a news tip about the courts? If you have information to share about the Supreme Court or other federal courts, please contact us.
Bayer has also said it cannot add warnings to Roundup in any state because they would contradict the E.P.A.’s findings.
In a brief to the justices, lawyers for Bayer wrote that the E.P.A. had “repeatedly determined” that glyphosate does not cause cancer, asserting that the company would not be able to “unilaterally alter the label’s precautionary warnings to include a cancer warning.”
The company appealed the jury verdict in the Missouri case and, after the Missouri Court of Appeals upheld the trial court, asked the justices to weigh in.
Early this year, President Trump issued an executive order that cited the Defense Production Act to guarantee production of glyphosate-based herbicides, appearing to elevate Roundup to a national security priority.
Lawyers for Mr. Durnell argued that nothing in the federal law blocked Bayer from adding a cancer warning to its labels and that such a change would not require E.P.A. approval.
Mr. Durnell was represented by Ashley C. Keller and Jonathan F. Mitchell, a prominent conservative appellate lawyer who represented Mr. Trump in his successful 2024 bid to remain on the Colorado ballot. Both lawyers joined the Supreme Court case only in recent months.
Another lawyer, David C. Frederick, had initially filed briefs on Mr. Durnell’s behalf. In the weeks before the argument, Mr. Frederick asked the justices if he could participate in the argument on behalf of more than 11,500 other people whose claims would be affected by the court’s decision. The justices denied the request.
-
Boston, MA6 minutes ago99 Restaurant in Charlestown may close for apartments
-
Denver, CO12 minutes agoRe/Max to be sold, headquarters to leave Denver
-
Seattle, WA18 minutes agoSeattle’s drug diversion plan falters as open-air use persists in neighborhood hotspots
-
San Diego, CA24 minutes agoMojo, San Diego’s pro volleyball team, will cease operations after 2026 season
-
Milwaukee, WI30 minutes agoThree Milwaukee youth now charged in Walker’s Point homicide
-
Atlanta, GA36 minutes agoConversation with Daryl “Chill” Mitchell
-
Minneapolis, MN42 minutes agoHCMC closing: Lawmakers weigh sales tax
-
Indianapolis, IN48 minutes agoLarry D. Hunter, age 80 of Indianapolis – WRBI Radio